



Curriculum vitae  
Europass

Informații personale

Nume / Prenume

**GALEȘ LAURENȚIA NICOLETA**

Adresă(e)

Str. Slt. Ionescu Gheorghe Nr. 7 Bl 140, Sc1, Ap 27, Sector 4, Bucuresti,  
Romania

Telefon(oane)

+40722651583

Fax(uri)

E-mail(uri)

[laurentia.gales@yahoo.com](mailto:laurentia.gales@yahoo.com);  
[laurentia.gales@gmail.com](mailto:laurentia.gales@gmail.com),  
[laurentia.gales@umfcd.ro](mailto:laurentia.gales@umfcd.ro), [Iminea51269@yahoo.ca](mailto:Iminea51269@yahoo.ca)

Naționalitate(-tăți)

română

Data nașterii

05 dec 1969

Sex

F

Locul de muncă vizat /  
Domeniul ocupațional

UMF Carol Davila București  
Institutul Oncologic Prof Dr Al Trestioreanu București  
Medicină

Experiența profesională

Perioada

**2016 – prezent – Conferențiar universitar - UMF Carol Davila București**  
2015 – Doctor în medicină  
2015 – Medic specialist radioterapie  
2009 – 2016 – Șef lucrări - UMF Carol Davila București  
2003-2009 – Asistent universitar - UMF Carol Davila București

Funcția sau postul ocupat

**Oct 2021 – prezent – Director Medical - Institutul Oncologic Prof Dr Al Trestioreanu București**  
**2008-prezent - Medic primar oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București**  
2003-2008 - Medic specialist oncologie medicală – Institutul Oncologic Prof Dr Al Trestioreanu București  
2002-2003 - Oncolog medical – Ambulatoriul Sp. Cl. Sf. Ioan București  
1997-2002 - Rezident oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București  
Conferențiar - UMF Carol Davila București  
Medic primar oncologie medicală - Institutul Oncologic Prof Dr Al Trestioreanu București – Director medical

Activități și responsabilități  
principale

Activitate medicală – diagnostic și tratament pacienți oncologici  
Activitate didactică – predare și îndrumare studenți și rezidenți oncologie  
Activitate de cercetare – studii clinice

Numele și adresa angajatorului	UMF Carol Davila București – Bulevardul Eroii Sanitari Nr. 8, Sector 5 București Institutul Oncologic Prof Dr Al Trestioreanu București – Șoseaua Fundeni Nr 252 Sector 2 București
Tipul activității sau sectorul de activitate	Medicină
Educație și formare	
Perioada	2015
Calificarea / diploma obținută	Titlul de Doctor în Medicină
Disciplinele principale studiate / competențe profesionale dobândite	Domeniul Oncologie
Numele și tipul instituției de învățământ / furnizorului de formare	UMF Carol Davila București – Școala Doctorală
Perioada	2015
Calificarea / diploma obținută	Medic specialist radioterapie 1152/mar 2015
Disciplinele principale studiate / competențe profesionale dobândite	Radioterapie
Numele și tipul instituției de învățământ / furnizorului de formare	Institutul Oncologic Prof Dr Al Trestioreanu București
Perioada	2008 - prezent
Calificarea / diploma obținută	Medic primar oncologie medicală 398/15/12.2008 B06-1012/4
Disciplinele principale studiate / competențe profesionale dobândite	Oncologie medicală
Numele și tipul instituției de învățământ / furnizorului de formare	Institutul Oncologic Prof Dr Al Trestioreanu București
Perioada	1997-2002
Calificarea / diploma obținută	Medic specialist oncologie medicală 256/03.2002
Disciplinele principale studiate / competențe profesionale dobândite	Oncologie medicală
Numele și tipul instituției de învățământ / furnizorului de formare	Institutul Oncologic Prof Dr Al Trestioreanu București
Perioada	1990 - 1995
Calificarea / diploma obținută	Doctor medic
Disciplinele principale studiate / competențe profesionale dobândite	Medicină generală N023109

Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea Ovidius Constanța																				
Nivelul în clasificarea națională sau internațională																					
Aptitudini și competențe personale																					
Limba(i) maternă(e)	română																				
Limba(i) străină(e) cunoscută(e)																					
Autoevaluare																					
<i>Nivel european (*)</i>	<table border="1"> <thead> <tr> <th colspan="2">Înțelegere</th> <th colspan="2">Vorbire</th> <th>Scriere</th> </tr> <tr> <th>Ascultare</th> <th>Citire</th> <th>Participare la conversație</th> <th>Discurs oral</th> <th>Exprimare scrisă</th> </tr> </thead> <tbody> <tr> <td>C1</td> <td>B2</td> <td>C1</td> <td>B2</td> <td>B2</td> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	Înțelegere		Vorbire		Scriere	Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă	C1	B2	C1	B2	B2					
Înțelegere		Vorbire		Scriere																	
Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă																	
C1	B2	C1	B2	B2																	
Engleza																					
Limba																					
	(*) <a href="#"><u>Nivelul Cadrului European Comun de Referință Pentru Limbi Străine</u></a>																				
Competențe și abilități sociale																					
Competențe și aptitudini organizatorice	Școala Națională de Studii Politice și Administrative – Studii Academice Postuniversitare – științe administrative – 2003-2006																				
Competențe și aptitudini tehnice																					
Competențe și aptitudini de utilizare a calculatorului	Utilizare windows, office (word, power point, excell, etc.)																				
Competențe și aptitudini artistice																					
Alte competențe și aptitudini	<ul style="list-style-type: none"> <li>- Centrul Național de Perfecționare Postuniversitară a Medicilor, Farmaciștilor, Altei Personal cu Studii Superioare și Asistenților Medicali - Curs de pregătire pentru dobândirea competenței în Îngrijiri paliative – 2003 – 2005</li> <li>- Ministerul Sănătății – Școala Națională de Sănătate Publică, Management și Perfecționare în Domeniul Sanitar București – Atestat în Managementul Serviciilor de Sănătate – 27.09.2021 – 09.03.2022</li> </ul>																				
Permis(e) de conducere	Permis categoria B																				
Informații suplimentare																					

## **Membră Societăți profesionale naționale și internaționale:**

ESMO (European Society of Medical Oncology) din 2000

ASCO (American Society of Clinical Oncology) din 2001

SIOG (International Society of Geriatric Oncology), din 2018, National representative – 2018-2019

RSM (The Royal Society of Medicine) din Marea Britanie

SNOMR (Societatea Națională de Oncologie Medicală din România)

SRR (Societatea Română de Radioterapie)

SRROM (Societatea Română de Radioterapie și Oncologie Medicală)

Colegiul Medicilor din România

Colegiul Medicilor din Municipiul București

## **Teza de Doctorat**

Studiul, cercetarea și aplicarea în clinica oncologică a tratamentului prin captarea neutronilor de către B-10

## **Lista lucrărilor științifice Anexa 1**

**Cărți și capitole din cărți: autor/ coautor capitole – 8 carti**

**Articole/studii in extenso publicate în reviste cotate ISI, indexate PubMed sau alte BDI, CNCSIS: - 71**

**Publicații in extenso, apărute în lucrări ale principalelor conferințe internaționale de specialitate și rezumate ale lucrărilor prezentate la conferințe internaționale de specialitate, publicate în reviste cotate ISI - 91**

**Alte lucrări și contribuții științifice: - 129 lucrari prezentate la conferinte nationale sau regionale**

**Cercetare: 3 proiecte de cercetare cu finanțare națională**

1. BNCT. Studiul, cercetarea si abordarea in clinica oncologica a radioterapiei cu neutroni captati de catre Bor-10 – PC-D01-PT11-94 (2005)
2. TARD. Dezvoltarea si testarea unui sistem automat de analiza a riscului, diagnoza si decizie pentru asistarea actului medical – PC-D03-PT03-1244 (2005)
3. Proiect VIASAN 435 – “Testarea genetica la femeile cu risc de neoplasm mamar ereditar” – Proiect al fundatiei Dr V Babes cu Partener Institutul Oncologic A Trestioreanu Bucuresti – responsabil de proiect

**Studii clinice: 50 studii clinice internaționale**

Ca SubInvestigator:

1. H3E-MC-JMEN Maintenance Therapy Studiu de faza 3, dublu-orb, controlat placebo, al pemetrexed de intretinere plus cea mai buna asistenta suportiva versus cea mai buna asistenta suportiva imediat dupa tratamentul de inducere pentru cancer pulmonar avansat fara celule mici
2. CECOG/ GIST 1.2.001 Studiu clinic deschis utilizand Glivec la pacienti cu tumori gastrointestinale neoperabile sau metastatice maligne cu c-kit exprimat
3. H3E-MC-JMDV Studiu clinic de faza ½ privind cresterea dozei de Alimta si Cyclophosphamida administrate la fiecare 21 de zile la pacientele cu cancer de san local avansat sau metastatic
4. 3066A1-303-WW Studiu de faza 3 randomizat, controlat placebo, dublu-orb al administrarii orale a CCI-779 in combinatie cu Letrozole versus Letrozole singur ca terapie hormonala de prima linie la femeile postmenopauza cu cancer de san local avansat sau metastatic
5. CECOG/CORE 1.2.001 Studiu de faza II, deschis, randomizat care evalueaza eficacitatea si siguranta folosirii tratamentului cu FOLFOX 6 + CETUXIMAB versus FOLFIRI + CETUXIMAB ca prima linie de tratament la pacientii cu cancer colorectal metastazat.

6. MO18024 Tratament de prima linie cu bevacizumab in combinatie cu chimioterapia in cancerul colorectal metastatic
7. A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer – H3E-MC-JMHO
8. EFC10547 – VANILLA - A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer
9. H3E-MC-JMHR A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
10. CECOG/CORE 1.2.002 A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + Weekly Cetuximab versus FOLFOX4 + biweekly Cetuximab as first line therapy in patients with k-ras wild-type metastatic colorectal cancer
11. KF5503/15 A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignant tumor-related pain
12. EMR 63325 A multi-center phase III randomized, double blind placebo-controlled study of the cancer vaccine Stimuvax (L-BLP25 or BLP25 liposome vaccine) in non-small cell lung cancer (NSCLC) subjects with unresectable stage III disease.
13. CECOG/BC.1.3.005: -“A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer”
14. BO21990 - A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma - AVAGLIO
15. A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting – PHEREX
16. CELLTRION CT-P6 - 3.1 / A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer
17. A randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition of Cp-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer – A4021017
18. EFC 11784 - Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m<sup>2</sup> and at 20 mg/m<sup>2</sup> in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy
19. EFC11785 / randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m<sup>2</sup> and at 25 mg/m<sup>2</sup> Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration resistant Prostate cancer Previously Treated With a Docetaxel-Containing Regimen.
20. Efficacy and Safety of long-Term (6 Months) Innohep® Treatment versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT
21. AMG 386 Protocol No. 20090508 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women with Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
22. An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy.
23. A Phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
24. A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7,5 mg/kg/day to dacarbazine in the treatment of

patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit.

25. A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer. – AMG20100007
26. BROCADE - A Randomised, Phase 2 Study of the Efficacy and Tolerability of Veliparib in combination with Temozolomide or Veliparib in combination with Carboplatin and Paclitaxel versus Placebo plus Carboplatin and Paclitaxel in Subjects with BRCA 1 or BRCA 2 Mutation and Metastatic Breast Cancer.
27. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy
28. A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy
29. MK-0517-031 AM4 - A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
30. A double-blind placebo-controlled, randomized, multicentric, Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2 – positive metastatic gastroesophageal junction and gastric cancer JACOB, BO25114
31. A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)
32. NBTXR-301 Multicenter randomized, open-label phase II/III study, to compare efficacy of NBTXR3 implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma (extremity and trunk wall)
33. CheckMate 9LA - A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
34. CheckMate 907 - An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen
35. CheckMate 743 - A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
36. CheckMate 227 - An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
37. CheckMate 915 - A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
38. CARMEN-LC03 - Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors
39. ALTA-3 - A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
40. ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Ca Investigator principal

41. BESTFACT – Bonefos Treatment for Advanced Cancer – Studiu non-interventional, observational, post-autorizare despre utilizarea Bonefos (disodium clodronate) administrat oral in tratamentul tumorilor maligne cu afectare osoasa, in conditiile practicii medicale curente.
42. Studiu clinic multicentric, deschis, de faza II, evaluand eficacitatea tratamentului cu Tarceva prescris ca monoterapie, in linia 1, la pacientii cu tip de cancer NSCLC ce prezinta mutatii la nivelul receptorului EGFR – ML22606
43. CRAD001YIC04 An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane
44. MK3475-059 A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
45. GO29294 A phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy [imvigor211]
46. CORAIL Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer
47. A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
48. ARCHES – A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
49. GLOW - A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
50. NERO – Impact of the Adherence to Antiemetic Guidelines in Cancer Patients Undergoing Repeated Cycles of Either MEC or HEC Regimens in Eastern Europe